EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

Tanishq Verma, Anuradha Mehra iD, Amit Mittal iD

Chemistry & Biodiversity · 2026

DOI: 10.1002/cbdv.202502968 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Tanishq Verma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India. Hauptthemen laut MEDLINE: Indoles, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide, cancer is a leading cause of morbidity and mortality. While multiple EGFR inhibitors have emerged, their therapeutic efficacy is constrained by the development of drug resistance and long‐term toxicity. Indoles have been identified as one of the promising scaffold classes to compete against EGFR in terms of selectivity and potency. They are favorable for anticancer drug discovery because they are structurally plastic, possess favorable pharmacokinetics, and bind to the ATP‐binding pocket of EGFR. Indole derivatives inhibit the auto‐phosphorylation of EGFR, thereby exhibiting their activity against cancers by blocking cancer cell proliferation, survival, and metastasis. The translation potential of this scaffold is also supported by the clinical success of indole‐based EGFR inhibitors, including the third‐generation drug osimertinib. Recent advances in molecular docking, structure–activity relationship studies, and hybrid drug design highlight the potential of indole‐based scaffolds to address resistance mutations while minimizing side effects. This paper summarizes the relevant literature of indole EGFR inhibitors published between 2021 and 2025, which may include mechanistic insights, biological screening, and therapeutic potential. The indole scaffold can be a useful starting point to push forward the next generation of targeted cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesAntineoplastic AgentsProtein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipNeoplasmsCell ProliferationAnimalsMolecular Structure

Stichwörter der Autor:innen

EGFRcancercytotoxicdrug resistanceindolemechanism

Substanzen

IndolesErbB ReceptorsAntineoplastic AgentsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.

ORCID-Profile: Anuradha Mehra, Amit Mittal

Zitieren

APA

Verma, T., Mehra, A., & Mittal, A. (2026). Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502968

Vancouver

Verma T, Mehra A, Mittal A. Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202502968

BibTeX
@article{Verma2026,
  author = {Verma, Tanishq and Mehra, Anuradha and Mittal, Amit},
  title = {Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  doi = {10.1002/cbdv.202502968}
}
Kostenlos starten →